Model Introduction
The Paclitaxel-Induced Neuropathic Pain (CIPNP) model is a vital tool for studying chemotherapy-induced peripheral neuropathy. This model induces significant mechanical allodynia and cold allodynia in experimental animals through intraperitoneal injection of paclitaxel. Since the pathogenesis involves signaling of key pro-inflammatory cytokines such as TNF-α, IL-1, and MCP-1—and pharmacological blockade of these signals effectively alleviates pain—the model is highly relevant to inflammatory pain in terms of pathophysiological mechanisms and serves as an effective surrogate for inflammatory pain research.
Research Applications
- Pathogenesis Exploration: Studying the role of inflammatory signaling (e.g., TNF-α, IL-1, and MCP-1) in the development of pain.
- Drug Screening and Evaluation: Screening for analgesics or anti-inflammatory interventions that can alleviate chemotherapy-induced pain and improve patient quality of life.
- Pathophysiological Research: Simulating peripheral neuropathy symptoms in patients receiving chemotherapy and studying the link between neurological abnormalities and inflammatory responses.
Key Points of Experimental Design
- Species: SD rats.
- Method: Intraperitoneal (i.p.) injection.
- Key Steps:
- Dose: 1 mg/kg.
- Frequency: One injection every other day for a total of four doses (Days 1, 3, 5, and 7).
- Characteristics:
- Animals typically maintain good health, exhibiting normal posture, grooming, and motor behavior.
- Normal weight gain is observed without significant neurological abnormalities, self-mutilation, or autotomy.
Key Monitoring Indicators
- Behavioral Evaluation:
- Mechanical allodynia tests.
- Cold allodynia tests.
- Spontaneous pain observation (e.g., spontaneous paw lifting).
- Thermal hyperalgesia tests.
- Physiological and Motor Monitoring:
- Body weight monitoring.
- Motor coordination and posture observation.
- Molecular Biology Indicators:
- TNF-α, IL-1, and MCP-1 signaling levels.
- Other Indicators:
- No records available based on current data.
